News

Zacks Investment Research on MSN15d
SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma
Sanofi SNY announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion recommending the approval of its blood cancer drug, ...
Morningstar4mon
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU - Morningstar
STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Zacks Investment Research on MSN14d
CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication
Novo Nordisk NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that Ozempic’s (once-weekly ...
PMLive12d
Sanofi’s Sarclisa recommended by CHMP for new multiple myeloma indication
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be approved in combination with ...
MarketWatch19d
Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval
By Colin Kellaher. Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with ...
PMLive13d
Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be authorised to treat unresectable ...
Morningstar4mon
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease - Morningstar
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease PR Newswire TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 ...
Nasdaq4mon
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease - Nasdaq
TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025/ PRNewswire/-- Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency ...
Medindia4mon
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU
STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Nasdaq4mon
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU - Nasdaq
--BioArctic AB's partner Eisai today announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has reaffirmed its positive opinion for the anti-Aβ ...
Mena FN4mon
The Committee For Medicinal Products For Human Use (CHMP) Reaffirms Positive Opinion For Lecanemab In Early Alzheimer's Disease - MENAFN.COM
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease Tuesday, 02 January 2024 12:17 GMT عربي ...